What is iovera°?
iovera is a pioneering medical device company specializing in cryoneurolysis technology. The firm provides a targeted, drug-free alternative to traditional pain management, specifically addressing conditions such as osteoarthritis and post-surgical recovery. By applying extreme cold to peripheral nerves, the iovera system effectively blocks pain signals for up to 90 days. This non-opioid approach is increasingly relevant in modern healthcare, where hospitals and outpatient clinics are prioritizing patient safety and reduced reliance on pharmaceutical interventions. The company's market position is defined by its ability to offer a repeatable, localized treatment that enhances patient quality of life across various anatomical applications, including the knee, hip, shoulder, and spine.
How much funding has iovera° raised?
iovera° has raised a total of $72.6M across 6 funding rounds:
Debt
$2.2M
Private Equity
$18.8M
Private Equity
$32.7M
Private Equity
$10M
Debt
$8.4M
Unspecified
$556K
Debt (2010): $2.2M, investors not publicly disclosed
Private Equity (2011): $18.8M, investors not publicly disclosed
Private Equity (2012): $32.7M supported by DeNovo Ventures, Accuitive Medical Ventures, Medicis Capital, and Saratoga Ventures, L.P.
Private Equity (2013): $10M featuring Medicis Capital Group, Valiance Asset Management Limited, DeNovo Ventures, and Accuitive Medical Ventures
Debt (2014): $8.4M backed by NMT Capital
Unspecified (2017): $556K, investors not publicly disclosed
Key Investors in iovera°
Accuitive Medical Ventures
A venture capital firm with $230 million in committed capital, specializing in revolutionary medical device technology and venture financing for companies with outstanding teams.
Medicis Capital Group
A strategic and operational expert in the healthcare sector, focusing on Pharma, Biotech, and MedTech companies in Western Europe.
NMT Capital
A globally oriented private equity firm managing investment funds with a focus on medical technology, life sciences, and advanced materials.
What's next for iovera°?
With the support of its strategic backers, iovera is well-positioned to accelerate its commercialization efforts and deepen its penetration into the orthopedic and pain management markets. The current funding context suggests a focus on scaling manufacturing capabilities and expanding clinical evidence to support broader adoption in hospital systems. As the company moves into its next phase of growth, the emphasis will likely remain on optimizing the delivery of its cryoneurolysis system and exploring new therapeutic indications. By maintaining its commitment to non-opioid innovation, iovera is poised to capture significant market share as healthcare providers continue to seek effective, long-lasting, and non-invasive pain relief alternatives.
See full iovera° company page
